Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers
- 1Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences , ,
- 2National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Science , ,
- 3Geriatrics Dept, Zhongshan Hospital of Traditional Chinese Medicine , ,
Abstract
Apolipoprotein B (ApoB) serves as the structural backbone of triglyceride (TG)-rich lipoproteins and low-density lipoprotein (LDL) particles and plays a key role in lipid transport. A growing body of evidence indicates that circulating ApoB levels are closely associated with the development of cardiovascular diseases such as coronary atherosclerosis, and ApoB may be one of the most accurate markers for assessing atherosclerotic cardiovascular disease (ASCVD) risk. This review discusses the limitations of conventional lipid measures, including low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and triglycerides (TG), and systematically examines the advantages of ApoB as an alternative marker for cardiovascular risk assessment, as well as its independent predictive value. In addition, this review discusses the clinical utility, potential advantages, and challenges associated with ApoB, as well as the effects of currently available lipid-lowering therapies on ApoB and recent advances in the development of ApoB-targeted therapies, with the aim of informing more precise strategies for the prevention and treatment of cardiovascular disease.
Related
- Beyond Traditional Risk Scores: Precision Medicine for Comprehensive Cardiovascular Risk Assessment in Women and Men
- A novel nutritional index is associated with adverse outcomes in patients with acute heart failure: insights beyond traditional risk markers
- Systemic Sclerosis-Specific Determinants of Major Adverse Cardiovascular Events: Development of an Exploratory Cardiovascular Risk Model Beyond Traditional Risk Factors.
- Association of glycated apolipoprotein A1 and low-density lipoprotein cholesterol levels with coronary disease severity and cardiovascular events in type 2 diabetes
- Thyroid-Stimulating hormone and metabolic cardiovascular risk markers from weighted two-wave analyses of india with an exploratory Chinese inpatient comparison
BibTeX
@article{li2026apolipoprotein,
title = {{Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers}},
author = {Lingling Li and Yixuan Feng and Xiaoya Li and Zongliang Yu and Changxin Sun and Lanqing Hu and Kaidong Zhou and Xinyi Liu and Yongfang Yuan and Liang Li and Min Wu and Longtao Liu},
journal = {Frontiers in cardiovascular medicine},
year = {2026},
month = sep,
doi = {10.3389/fcvm.2026.1857230},
url = {https://europepmc.org/article/PMC/PMC13662374},
note = {CC BY},
}
RIS
TY - JOUR
TI - Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers
AU - Lingling Li
AU - Yixuan Feng
AU - Xiaoya Li
AU - Zongliang Yu
AU - Changxin Sun
AU - Lanqing Hu
AU - Kaidong Zhou
AU - Xinyi Liu
AU - Yongfang Yuan
AU - Liang Li
AU - Min Wu
AU - Longtao Liu
PY - 2026
DA - 2026/09/30
JO - Frontiers in cardiovascular medicine
DO - 10.3389/fcvm.2026.1857230
UR - https://europepmc.org/article/PMC/PMC13662374
AB - Apolipoprotein B (ApoB) serves as the structural backbone of triglyceride (TG)-rich lipoproteins and low-density lipoprotein (LDL) particles and plays a key role in lipid transport. A growing body of evidence indicates that circulating ApoB levels are closely associated with the development of cardiovascular diseases such as coronary atherosclerosis, and ApoB may be one of the most accurate markers for assessing atherosclerotic cardiovascular disease (ASCVD) risk. This review discusses the limitations of conventional lipid measures, including low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and triglycerides (TG), and systematically examines the advantages of ApoB as an alternative marker for cardiovascular risk assessment, as well as its independent predictive value. In addition, this review discusses the clinical utility, potential advantages, and challenges associated with ApoB, as well as the effects of currently available lipid-lowering therapies on ApoB and recent advances in the development of ApoB-targeted therapies, with the aim of informing more precise strategies for the prevention and treatment of cardiovascular disease.
SN - 2297-055X
ER -